Antares’ Overactive Bladder Gel Faces Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Antares expects to submit an NDA for its oxybutynin gel product Anturol for overactive bladder by the end of 2007, the firm said June 26